
FDA spike: clinic supplier Liveyon warning letter & 483s; notice on exosome harms
Friday and Saturday showed a burst in FDA activity related to unproven stem cells and regenerative products including a warning letter to the unproven perinatal “stem cell” provider Liveyon. This was an unusual 48-hour period and a very good one […]